Lipella Pharmaceuticals Inc. (LIPO) Stock Price & Analysis
Lipella Pharmaceuticals Inc. (LIPO) — price $0.0004 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Lipella Pharmaceuticals Inc. · LIPO
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on reformulating existing generic drugs for new applications. Their lead product candidates target unmet needs in radiation-induced hemorrhagic cystitis and oral lichen planus.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0004 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0002 – $0.542 | |
| Shares traded on the day | 160.1K |
Price & events
Other perspectives
Council score for Lipella Pharmaceuticals (LIPO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
1 lens, 1 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Lipella Pharmaceuticals (LIPO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lipella Pharmaceuticals Inc. (LIPO) is the company analyzed here. It employs 7 people and is led by Jonathan Kaufman. In Q4 FY2024 it reported revenue of $173,666 and net income of -$1M.
What do the latest results show for Lipella Pharmaceuticals (LIPO)?
Short answer · as of
The most recent reported quarter, Q4 FY2024, carried revenue of $173,666. Against analyst estimates the company has EPS beat 3 of the last 6 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2024 | $173,666 | -$1M | -$1.37 (diluted) |
What are the financial strengths and risks for Lipella Pharmaceuticals (LIPO)?
Short answer · as of
The distress and quality screens read Altman Z -18.13 · Piotroski F 1. Trailing ratios: current ratio 3.24.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -18.13 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Lipella Pharmaceuticals (LIPO)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $583,664 · EPS -17.42 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q4 FY2024) was filed Mar 28, 2025 — 11 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $583,664
- EPS estimate
- $-17.42
Measured against a quoted price of $0.0004 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LIPO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LIPO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About LIPO
These answers are editorial: 1 of these 1 answer is drawn from the LIPO research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
How does Lipella Pharmaceuticals Inc. manage patent expiration risks?
Lipella Pharmaceuticals Inc. focuses on reformulating existing generic drugs, which inherently involves navigating the patent landscape. While the active ingredients are already off-patent, Lipella seeks to obtain new patents on its specific formulations, delivery methods, or therapeutic uses. This strategy aims to create a period of market exclusivity for its products, even though the underlying drug is generic.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 7 from Financial Modeling Prep (FMP) and 9 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com